Eli Lilly & Co. and Novo Nordisk A/S secured deals with the Trump administration to slash prices for their weight-loss drugs in exchange for tariff relief and wider access for Medicare patients. President Trump spoke about the deal earlier today from the Oval Office. The companies’ products will receive a three-year grace period from Trump’s forthcoming duties on pharmaceutical imports and will be available to certain people on Medicare at a lower cost. Bloomberg’s Robert Langreth joined Norah Mulinda and Bailey Lipschultz on ‘Bloomberg Businessweek Daily’ to break it down.
——–
Watch Bloomberg Radio LIVE on YouTube
Weekdays 7am-6pm ET
WATCH HERE: http://bit.ly/3vTiACF
Follow us on X: https://twitter.com/BloombergRadio
Subscribe to our Podcasts:
Bloomberg Daybreak: http://bit.ly/3DWYoAN
Bloomberg Surveillance: http://bit.ly/3OPtReI
Bloomberg Intelligence: http://bit.ly/3YrBfOi
Balance of Power: http://bit.ly/3OO8eLC
Bloomberg Businessweek: http://bit.ly/3IPl60i
Listen on Apple CarPlay and Android Auto with the Bloomberg Business app:
Apple CarPlay: https://apple.co/486mghI
Android Auto: https://bit.ly/49benZy
Visit our YouTube channels:
Bloomberg Podcasts: https://www.youtube.com/bloombergpodcasts
Bloomberg Television: https://www.youtube.com/@markets
Bloomberg Originals: https://www.youtube.com/bloomberg
Quicktake: https://www.youtube.com/@BloombergQuicktake
